Effect of letrozole cotreatment in progestin-primed ovarian stimulation on IVF/ICSI outcomes in POSEIDON group 3 and 4 poor responders: a retrospective cohort study
Open Access
- 22 April 2025
- journal article
- research article
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1-12
Abstract
For poor ovarian response patients, obtaining higher number of transferable and high-quality embryos is crucial and progestin-primed ovarian stimulation protocol is becoming widespread and constantly improving in this population. Letrozole has shown promise in numerous protocols and individuals. This study aims to evaluate the effect of the early addition of letrozole in progestin-primed ovarian stimulation protocol among expected poor ovarian response patients. This retrospective cohort study was performed in POSEIDON group 3 and 4 patients who underwent in vitro fertilization or intracytoplasmic sperm injection with their first progestin-primed ovarian stimulation protocol from January 1, 2018 to December 31, 2021. Totally 557 patients were enrolled in this research with 189 ovarian stimulation cycles for POSEIDON group 3 patients and 368 ovarian stimulation cycles for POSEIDON group 4 patients. The primary outcome of this study was the cumulative live birth rate and cumulative clinical pregnancy rate, and the second outcomes included the laboratory outcomes and pregnancy outcomes, maternal and neonatal complications also were encompassed. In this study, progestin-primed ovarian stimulation protocol combined with letrozole (study group) was associated with a significantly higher number of oocytes for retrieval and maturation [3.0 (2.0, 5.0) vs. 2.0 (1.3, 4.0), P < 0.001; 3.0 (2.0, 5.0) vs. 2.0 (1.0, 3.8), P < 0.001] as well as 2PN embryos [2.0 (1.0, 3.0) vs. 2.0 (1.0, 3.0), P = 0.026] among POSEIDON group 4 patients. In POSEIDON group 3 patients, the letrozole cotreatment did not show an advantage in these indicators. There was no significant difference in both cumulative live birth rate and cumulative clinical pregnancy rate between the study and control group in POSEIDON group 3 and 4 patients. Multivariate logistic regression model showed that significant favorable effects of the number of available embryos on cumulative live birth rate in all included patients. These findings indicate that advanced-aged poor ovarian response patients may benefit more from using letrozole as an advantageous adjuvant agent in the progestin-primed ovarian stimulation protocol to obtain more oocytes and embryos in clinical practice. Trial registration This trial was retrospectively registeredKeywords
Funding Information
- the national key Research and Development Program of China (2022YFC2702503)
- the International Science and Technology Cooperation Project of Hubei Province, China (2021EHB025)
This publication has 42 references indexed in Scilit:
- Effects of letrozole co-treatment on outcomes of gonadotropin-releasing hormone antagonist cycles in POSEIDON groups 3 and 4 expected poor respondersArchives of Gynecology and Obstetrics, 2022
- Effects of using letrozole in combination with the GnRH antagonist protocol for patients with poor ovarian response: A meta-analysisJournal of Gynecology Obstetrics and Human Reproduction, 2021
- The addition of clomiphene citrate to ovarian stimulation protocols for poor respondersEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2020
- A review of the physiology behind letrozole applications in infertility: are current protocols optimal?Journal of Assisted Reproduction and Genetics, 2020
- Impact of progestin ovarian stimulation on newborn outcomes: a meta-analysisJournal of Assisted Reproduction and Genetics, 2020
- Reprint of: Blastocyst score affects implantation and pregnancy outcome: towards a single blastocyst transferFertility and Sterility, 2019
- Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization or intracytoplasmic sperm injectionFertility and Sterility, 2016
- A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis conceptFertility and Sterility, 2016
- Younger poor ovarian response women achieved better pregnancy results in the first three IVF cyclesReproductive BioMedicine Online, 2016
- Use of aromatase inhibitors in poor-responder patients receiving GnRH antagonist protocolsReproductive BioMedicine Online, 2009